Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 3 years ago

Possible Interaction: Deferoxamine and Iron, Dietary

Research Papers that Mention the Interaction

The results also reinforce the conclusion that DFO causes the excretion of substantially more iron than would be predicted by an assessment of serum ferritin levels or past compliance with chelation therapy.
Advances in experimental medicine and biology  •  1994  |  View Paper
Owing to its higher affinity to deferoxamine (DFO) and higher plasma concentrations, Fe could impair Al removal in cases of simultaneous body burden.
The 80-mg/kg dose of DFO significantly raised Al mass transfer in both groups, whereas Fe mass transfer was only slightly affected.
Thus, DFO once a week reduced Fe loss to less than 30 mumol/wk in patients with normal ferritin levels.
American journal of kidney diseases : the official journal of the National Kidney Foundation  •  1991  |  View Paper
In all 9 patients studied before transfusion, continuous subcutaneous infusion of 750 mg D.F. over 24 hours increased iron excretion by 61-5 to 135-8% (mean 101+/-25-4 S.D.%) compared with intramuscular injection of a similar dose.
The Lancet  •  1976  |  View Paper
Through its iron chelation effect, deferoxamine reduces iron availability in serum and body tissue which could prevent lung injury and fibrosis following COVID-19 infection.
European Journal of Clinical Pharmacology  •  2020  |  View Paper
Treatment with iron chelators desferrioxamine , deferiprone, and deferasirox) substantially improved cardiovascular morbidity and mortality in iron overloaded patients.
Current medicinal chemistry  •  2019  |  View Paper
Increasing evidence shows that DFO can inhibit the activity of proline hydroxylase (PHD) by chelating iron , resulting in hypoxia-induced factor (HIF) signaling activation and angiogenesis promotion.
Bone  •  2019  |  View Paper
Iron also completely prevented the decrease in BrdU incorporation induced by either DFO or MO-OH-Nap.
Leukemia research  •  2019  |  View Paper
Deferoxamine preferentially abrogates the intralysosomal accumulation of iron and inhibits oxidative stress-induced lysosomal membrane permeabilization and cell death.
Current drug metabolism  •  2015  |  View Paper
Chelation of iron via intranasal administration of DFO (200 mg/kg once every other day for 90 days) inhibited iron-induced amyloidogenic APP processing and reversed behavioral alterations.
Neurobiology of Aging  •  2013  |  View Paper
The coma is more severe in iron-deficient rats suggesting that removal of iron and resulting neuronal iron deficiency by desferrioxamine is a contributory cause.
Medical hypotheses  •  2011  |  View Paper
Show More